# Clinical Trial Landscape: 13_nsclc_alk_cns_disease

*Generated: 2026-01-05 07:00:55*

## Summary

- **Total Trials**: 68
- **Flagged for Review**: 0
- **Search Terms Used**: 8

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 21 | ██████ 30.9% |
| Phase 1 | 15 | ████ 22.1% |
| Phase 1/Phase 2 | 9 | ██ 13.2% |
| Phase 3 | 8 | ██ 11.8% |
| Unknown | 6 | █ 8.8% |
| Not Applicable | 6 | █ 8.8% |
| Phase 2/Phase 3 | 2 |  2.9% |
| Early Phase 1 | 1 |  1.5% |

## Status Distribution

- **Recruiting**: 67 (98.5%)
- **Enrolling by invitation**: 1 (1.5%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| M.D. Anderson Cancer Center | 4 |
| Mayo Clinic | 3 |
| Merck Sharp & Dohme LLC | 3 |
| National Cancer Institute (NCI) | 2 |
| SWOG Cancer Research Network | 2 |
| Hoffmann-La Roche | 2 |
| AbbVie | 2 |
| University of Colorado, Denver | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Amgen | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Turning Point Therapeutics, Inc. | 1 |
| Dana-Farber Cancer Institute | 1 |
| University of California, San Francisco | 1 |
| Canadian Cancer Trials Group | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Pembrolizumab | 8 |
| Carboplatin | 8 |
| Pemetrexed | 7 |
| Nivolumab | 5 |
| Osimertinib | 4 |
| Paclitaxel | 4 |
| Cisplatin | 4 |
| Questionnaire Administration | 3 |
| Magnetic Resonance Imaging | 3 |
| Biospecimen Collection | 3 |
| Computed Tomography | 3 |
| JAB-23E73 | 3 |
| Quality-of-Life Assessment | 2 |
| Durvalumab | 2 |
| Entrectinib | 2 |
| Docetaxel | 2 |
| Ramucirumab | 2 |
| Amivantamab (to be determined) | 2 |
| Sacituzumab tirumotecan | 2 |
| Tarlatamab | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 68 |
| South Korea | 17 |
| Japan | 16 |
| Spain | 15 |
| France | 14 |
| Australia | 13 |
| Taiwan | 13 |
| Canada | 12 |
| Italy | 12 |
| United Kingdom | 12 |
| China | 11 |
| Germany | 10 |
| Poland | 10 |
| Belgium | 9 |
| Brazil | 9 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| ALK rearrangement | manual | 1.0 |
| ALKrearrangement | manual | 0.9 |
| ALK-rearrangement | manual | 0.9 |
| NSCLC | manual | 1.0 |
| ALK rearrangement NSCLC | manual | 1.0 |
| ALK rearrangement non-small cell lung cancer | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| ALK-rearranged | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07155187](https://clinicaltrials.gov/study/NCT07155187) | Phase 2/Phase 3 | Recruiting | AbbVie | Phase 2/3 Open Label Randomized Stu... |
| [NCT07125183](https://clinicaltrials.gov/study/NCT07125183) | Phase 2 | Recruiting | University of Colora... | A Phase II Study on Efficacy and To... |
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | Not Applicable | Recruiting | VA Office of Researc... | Evaluating the Impact of Intermitte... |
| [NCT07132918](https://clinicaltrials.gov/study/NCT07132918) | Phase 2 | Recruiting | University of Wiscon... | The cARdiac Radiation Therapy Spari... |
| [NCT07140016](https://clinicaltrials.gov/study/NCT07140016) | Phase 1 | Recruiting | Astellas Pharma Glob... | A Phase 1b Study of Gilteritinib in... |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | Early Phase 1 | Recruiting | University of Texas ... | Feasibility Study of Personalized U... |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | Phase 1/Phase 2 | Recruiting | University of Arizon... | RAdiation comBined With BIspecific ... |
| [NCT06973564](https://clinicaltrials.gov/study/NCT06973564) | Phase 1/Phase 2 | Recruiting | Jacobio Pharmaceutic... | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Phase 3 | Recruiting | Children's Oncology ... | Risk Adapted Treatment of Unilatera... |
| [NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Phase 2 | Recruiting | Mayo Clinic | Phase 2 Study of Golcadomide With R... |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Phase 2 | Recruiting | Duke University | Safety, Efficacy, and Tumor Immune ... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT05669846](https://clinicaltrials.gov/study/NCT05669846) | Phase 2 | Recruiting | Diwakar Davar | Phase II Feasibility Study of Healt... |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Phase 2 | Recruiting | Amgen | A Phase 2 Study Evaluating the Effi... |
| [NCT06566443](https://clinicaltrials.gov/study/NCT06566443) | Phase 1 | Recruiting | The Methodist Hospit... | Phase I Trial Evaluating the Safety... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Phase 3 | Recruiting | Bristol-Myers Squibb | A Phase 3, Randomized, Open-label S... |
| [NCT06545331](https://clinicaltrials.gov/study/NCT06545331) | Phase 1 | Recruiting | Exelixis | A Dose-Escalation and Expansion Stu... |
| [NCT06252129](https://clinicaltrials.gov/study/NCT06252129) | Not Applicable | Recruiting | Brigham and Women's ... | Maximizing Lymph Node Dissection on... |
| [NCT06422143](https://clinicaltrials.gov/study/NCT06422143) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | Phase 3 Study of Pembrolizumab in C... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06124118](https://clinicaltrials.gov/study/NCT06124118) | Phase 1 | Recruiting | University of Utah | A Feasibility Study to Evaluate the... |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3 Randomized Open-Label Stu... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT06225804](https://clinicaltrials.gov/study/NCT06225804) | Phase 1 | Recruiting | Abbisko Therapeutics... | A Phase 1, Open-Label Study of ABSK... |
| [NCT06117774](https://clinicaltrials.gov/study/NCT06117774) | Phase 3 | Recruiting | Amgen | A Phase 3, Randomized, Double-blind... |
| [NCT06074588](https://clinicaltrials.gov/study/NCT06074588) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Randomized, Open-label, Phase 3 S... |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Phase 2 | Recruiting | Hackensack Meridian ... | A Multicenter Phase II Randomized T... |
| [NCT06007937](https://clinicaltrials.gov/study/NCT06007937) | Phase 1/Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 1/2 Study of Combination Lo... |
| [NCT05815173](https://clinicaltrials.gov/study/NCT05815173) | Phase 1 | Recruiting | NYU Langone Health | Phase I/II Study of Ladarixin and S... |
| [NCT05845671](https://clinicaltrials.gov/study/NCT05845671) | Phase 1/Phase 2 | Recruiting | University of Colora... | A Phase 1 / 2, Open Label, Study of... |
| [NCT05876923](https://clinicaltrials.gov/study/NCT05876923) | Not Applicable | Recruiting | Mayo Clinic | The Effects of Acute and Chronic Ex... |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Phase 2 | Recruiting | Memorial Sloan Kette... | Window of Opportunity Analysis of P... |
| [NCT05642572](https://clinicaltrials.gov/study/NCT05642572) | Phase 2 | Recruiting | SWOG Cancer Research... | A Randomized Phase II Study of INC2... |
| [NCT05544019](https://clinicaltrials.gov/study/NCT05544019) | Phase 1 | Recruiting | Schrödinger, Inc. | A Phase 1, Open-Label, Multicenter,... |
| [NCT05720117](https://clinicaltrials.gov/study/NCT05720117) | Phase 1 | Recruiting | Pyxis Oncology, Inc | A First-in-Human, Open-label, Multi... |
| [NCT05500092](https://clinicaltrials.gov/study/NCT05500092) | Phase 2 | Recruiting | Montefiore Medical C... | An Open Label, Randomized Study of ... |
| [NCT05514717](https://clinicaltrials.gov/study/NCT05514717) | Phase 1 | Recruiting | Mersana Therapeutics | A Phase 1, First-in-Human, Dose Esc... |
| [NCT05578326](https://clinicaltrials.gov/study/NCT05578326) | Phase 2 | Recruiting | UNC Lineberger Compr... | Study of Trilaciclib and Lurbinecte... |
| [NCT05168566](https://clinicaltrials.gov/study/NCT05168566) | Phase 2 | Recruiting | Teligene US | A Multicenter, Open-label, Phase II... |
| [NCT05261399](https://clinicaltrials.gov/study/NCT05261399) | Phase 3 | Recruiting | AstraZeneca | A Phase III, Randomised, Open-Label... |
| [NCT05419375](https://clinicaltrials.gov/study/NCT05419375) | Phase 2 | Recruiting | Hoffmann-La Roche | Master Screening Study to Determine... |
| [NCT05332925](https://clinicaltrials.gov/study/NCT05332925) | N/A | Recruiting | Jun Zhang, MD, PhD | Using Ex Vivo Tumoroids To Predict ... |
| [NCT04712877](https://clinicaltrials.gov/study/NCT04712877) | N/A | Recruiting | Lung Cancer Mutation... | LEADER Neoadjuvant Screening Trial:... |
| [NCT05384626](https://clinicaltrials.gov/study/NCT05384626) | Phase 1/Phase 2 | Recruiting | Nuvalent Inc. | A Phase 1/2 Study of the Selective ... |
| [NCT05076760](https://clinicaltrials.gov/study/NCT05076760) | Phase 1 | Recruiting | Memgen, Inc. | Phase I Study Evaluating MEM-288 On... |
| [NCT05118854](https://clinicaltrials.gov/study/NCT05118854) | Phase 2 | Recruiting | M.D. Anderson Cancer... | A Phase II Study of Neoadjuvant Sot... |
| [NCT05005403](https://clinicaltrials.gov/study/NCT05005403) | Phase 1 | Recruiting | AbbVie | A Global First-in-Human Study in NS... |
| [NCT04486833](https://clinicaltrials.gov/study/NCT04486833) | Phase 1/Phase 2 | Recruiting | Genprex, Inc. | A Phase 1/2 Open-Label, Dose-Escala... |

*... and 18 more trials (see trials.csv for full list)*
